Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Alfuzosin tablet composition

A technology for alfuzosin tablets and alfuzosin, which is applied in the directions of drug combination, pill delivery, urinary system diseases, etc. Moisture resistance, improved content uniformity

Inactive Publication Date: 2018-05-08
WEIHAI GUANBIAO INFORMATION TECH
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In the research process of alfuzosin ordinary tablets, it was found that alfuzosin belongs to small-scale preparations. During the preparation process of ordinary tablets, firstly, the content uniformity is not easy to meet the standard, and secondly, after long-term storage, the tablets are seriously hygroscopic. At the same time, the increase of related substances is prominent, which affects the safety and effectiveness of the tablet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alfuzosin tablet composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1, 2.5 g of alfuzosin, 20 g of lactose, 16 g of sodium carboxymethyl starch, 50 g of microcrystalline cellulose, 12 g of calcium citrate, 3 g of polyethylene glycol 4000, 1.2 g of magnesium stearate, according to the technical proposal The described preparation method prepares 1000 tablets g.

Embodiment 2

[0022] Embodiment 2, alfuzosin 2.5 g, lactose 40 g, sodium carboxymethyl starch 8 g, microcrystalline cellulose 30 g, calcium citrate 20 g, polyethylene glycol 4000 8 g, magnesium stearate 1.7 g, according to technical scheme 1000 tablets were prepared by the described preparation method.

Embodiment 3

[0023] Embodiment 3, alfuzosin 2.5g, lactose 32g, sodium carboxymethyl starch 14g, microcrystalline cellulose 40g, calcium citrate 15g, polyethylene glycol 4000 6g, magnesium stearate 1.5g, according to the technical proposal 1000 tablets were prepared by the described preparation method.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an alfuzosin tablet composition, and belongs to the technical field of pharmacy. The alfuzosin tablet composition is characterized in that the alfuzosin tablet composition ofa unit dose is prepared from 2.5 mg of alfuzosin, 20 to 40mg of lactose, 8 to 16mg of sodium carboxymethyl starch, 30 to 50mg of microcrystalline cellulose, 12 to 20mg of calcium citrate, 3 to 8mg ofpolyethylene glycol 4000 and 1.2 to 1.7mg of magnesium stearate. The invention provides the stable alfuzosin tablet composition.

Description

technical field [0001] The invention relates to an alfuzosin composition and belongs to the technical field of pharmacy. Background technique [0002] Hyperplasia of the prostate, often called benign prostatic hyperplasia (BPH), is one of the common diseases of middle-aged and elderly men, and its incidence is increasing with the aging of the global population. The incidence of benign prostatic hyperplasia increases with age, and most patients have symptoms such as dysuria that increase with age. [0003] Prostatic hypertrophy is also called benign prostatic hyperplasia. Symptoms are mainly manifested in two groups of symptoms, one is bladder irritation symptoms; the other is obstructive symptoms caused by prostatic hyperplasia blocking the urinary tract. Bladder irritation symptoms: urinary frequency, urgency, nocturia, and urge incontinence. Frequent urination is an early signal of benign prostatic hyperplasia, especially the increased frequency of nocturia is more clin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K31/517A61K47/10A61K47/12A61P13/08
Inventor 孙爱梅
Owner WEIHAI GUANBIAO INFORMATION TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com